Stock TERN TERNS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Terns Pharmaceuticals, Inc.

Equities

TERN

US8808811074

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-08 pm EDT 		5-day change 1st Jan Change
6.05 USD +5.03% Intraday chart for Terns Pharmaceuticals, Inc. +19.09% -6.78%
Apr. 29 Terns Pharmaceuticals, Inc. Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor Tern-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation CI
Apr. 10 Terns Pharmaceuticals, Inc. Appoints Melita Sun Jung as Chief Business Officer CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Terns Pharmaceuticals Announces Leadership Changes
GL
Terns Pharmaceuticals Announces Leadership Changes
AQ
Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024
GL
TERNS PHARMACEUTICALS REPORTS INDUCEMENT GRANT TO NEW EMPLOYEE UNDER NASDAQ LISTING RULE 5635(4)
AQ
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
GL
Terns Pharmaceuticals : Corporate Presentation April 2024
PU
Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
GL
Terns Pharmaceuticals, Inc. Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor Tern-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
CI
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
GL
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
AQ
Terns Pharmaceuticals, Inc. Appoints Melita Sun Jung as Chief Business Officer
CI
UBS Trims Terns Pharmaceuticals Price Target to $18 From $19, Maintains Buy Rating
MT
North American Morning Briefing : Stocks Struggle After New Records
DJ
JMP Securities Cuts Terns Pharmaceuticals Price Target to $15 From $17, Maintains Market Outperform Rating
MT
BMO Capital Adjusts Price Target on Terns Pharmaceuticals to $19 From $18, Maintains Outperform Rating
MT
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
GL
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Thinking about buying stock in Marathon Digital, Assertio, Ocean Biomedical, Terns Pharmaceuticals, or NextCure?
PR
Terns Pharmaceuticals Gets Orphan Drug Label for Chronic Myeloid Leukemia Treatment Candidate
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TERN Stock
  4. News Terns Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW